Flurbiprofen axetil

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Flurbiprofen axetil
DrugBank Accession Number
DB14938
Background

Flurbiprofen axetil is under investigation in clinical trial NCT02043366 (Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients).

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 330.355
Monoisotopic: 330.126737255
Chemical Formula
C19H19FO4
Synonyms
  • Flurbiprofen axetil

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Abciximab.
AcebutololFlurbiprofen axetil may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Flurbiprofen axetil.
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Flurbiprofen axetil.
AcenocoumarolThe risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Acenocoumarol.
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
I0OU31PUI5
CAS number
91503-79-6
InChI Key
ALIVXCSEERJYHU-UHFFFAOYSA-N
InChI
InChI=1S/C19H19FO4/c1-12(19(22)24-14(3)23-13(2)21)16-9-10-17(18(20)11-16)15-7-5-4-6-8-15/h4-12,14H,1-3H3
IUPAC Name
1-(acetyloxy)ethyl 2-{2-fluoro-[1,1'-biphenyl]-4-yl}propanoate
SMILES
CC(OC(C)=O)OC(=O)C(C)C1=CC(F)=C(C=C1)C1=CC=CC=C1

References

General References
Not Available
ChemSpider
3278
ChEBI
31627
ChEMBL
CHEMBL3183067

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
4CompletedPreventionCatheter Related Bladder Discomfort1somestatusstop reasonjust information to hide
4CompletedTreatmentPain1somestatusstop reasonjust information to hide
4CompletedTreatmentPostoperative pain1somestatusstop reasonjust information to hide
4TerminatedPreventionDelirium / Dexamethasone / Flubiprofen Axetil / Non-Small Cell Lung Carcinoma / Surgical Complications1somestatusstop reasonjust information to hide
4TerminatedSupportive CareDexamethasone / Flubiprofen Axetil / Long-Term Effects Secondary to Cancer Therapy in Adults / Non-Small Cell Lung Carcinoma / Surgery1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00186 mg/mLALOGPS
logP4.36ALOGPS
logP4.18Chemaxon
logS-5.2ALOGPS
pKa (Strongest Basic)-6.8Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area52.6 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity87.16 m3·mol-1Chemaxon
Polarizability34.15 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00bc-2090000000-2be155d853da9799273f
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-06dm-6290000000-830ef8e95d18e9e05d29
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a6r-9610000000-c848ee171f4a1907f94e
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-002b-0920000000-c9f4329126651aaa525d
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-00fu-3900000000-0281c8f57b5c363bab31
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-004j-2900000000-607a66ce543ce62e98bf
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-177.08641
predicted
DeepCCS 1.0 (2019)
[M+H]+179.44441
predicted
DeepCCS 1.0 (2019)
[M+Na]+186.71533
predicted
DeepCCS 1.0 (2019)

Drug created at May 20, 2019 14:36 / Updated at February 21, 2021 18:55